• The 5th annual E-Cigarette Summit will take place on Friday 17th November at The Royal Society, London
  • Registration for the E-Cigarette Summit 2017 is now open

Professor David Abrams

Executive Director, The Schroeder Institute for Tobacco Research and Policy Studies
Professor, The Johns Hopkins Bloomberg School of Public Health

David B. Abrams, PhD, is Executive Director of the Schroeder Institute for Tobacco Research and Policy Studies at Legacy. He is also a Professor in the Department of Health, Behavior and Society at the Johns Hopkins Bloomberg School of Public Health and Professor (Adjunct) at Georgetown University Medical Center/Lombardi Comprehensive Cancer Center. Previously, Dr. Abrams directed the Office of Behavioral and Social Sciences Research (OBSSR) at the National Institutes of Health. He holds a B.Sc. (honours) in Computer Science and Psychology from the University of Witwatersrand, South Africa, and a Doctorate in Clinical Psychology from Rutgers University, New Jersey. He has published over 250 scholarly articles. Dr. Abrams is author of The Tobacco Dependence Treatment Handbook: A Guide to Best Practices, a recipient of a book of the year award. He was President of the Society for Behavioral Medicine and received their Distinguished Scientist and Mentorship awards. Dr. Abrams also received the Joseph W. Cullen Memorial Award from the American Society for Preventive Oncology for lifetime contributions to tobacco control.

Dr. Abrams brings scientific expertise at the conceptual, basic, applied, policy and administrative levels. His current focus is on providing scientific leadership in tobacco control from a transdisciplinary perspective. Systems integration is arguably the single most critical missing ingredient needed to maximize the unrealized potential to reduce tobacco use prevalence. Specifically, he explores innovative ways to put what is known into widespread practice and policy to make an efficient impact on the population.

Recently, Dr. Abrams is focusing on the role research can play in informing policies for the regulation of tobacco products by the US Food and Drug Administration. This includes development of a strategic research agenda, convening content area experts, conducting knowledge synthesis and rapidly deploying research projects to address FDA mandates, such as whether mentholated cigarettes should remain on the market, evaluating the safety and consumer perceptions of e-cigarettes and tracking public perceptions of other potential and actual FDA regulations

Professor David Abrams will be speaking at:

Panel Discussion and Q&A: Can there be a balanced debate on e-cigarettes and harm reduction when there is no consensus on where the “middle ground” lies?

- 17:05 - 17:25

The importance of methodology to end circular arguments on e-cigarettes

- 16:40 - 16:45

« Back to previous page